

Applicant : Joseph R. Berger
Serial No. : 10/052,961
Filed : January 18, 2002
Page 2

In the Claims

Please amend the claims by replacing all prior versions of the claims pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as indicated below.

1-58. (Canceled)

59. (Currently Amended) A pharmaceutical composition for ameliorating myopathy, weight loss or muscle wasting resulting from chronic human immunodeficiency virus type-1 infection comprising oxandrolone and a pharmaceutically acceptable carrier, wherein the oxandrolone is present in the composition in an amount of 7.5 milligrams or more.

60. (Previously Presented) The pharmaceutical composition of claim 59, wherein the oxandrolone is present in the composition in an amount of 7.5 milligrams to 20 milligrams.

61. (Previously Presented) The pharmaceutical composition of claim 59, wherein the oxandrolone is present in the composition in an amount of 10 milligrams.

62. (Previously Presented) The pharmaceutical composition of claim 59, wherein the oxandrolone is present in the composition in an amount of 20 milligrams.

63. (Previously Presented) The pharmaceutical composition of claim 59, wherein the composition is in liquid or solid form.

64. (Previously Presented) The pharmaceutical composition of claim 59, wherein the oxandrolone is present in the composition in an amount of 20 milligrams.

65. (Previously Presented) The pharmaceutical composition of claim 61, wherein the composition is in solid form.

Applicant : Joseph R. Berger
Serial No. : 10/052,961
Filed : January 18, 2002
Page 3

66. (New) A pharmaceutical composition comprising oxandrolone and a pharmaceutically acceptable carrier, wherein the oxandrolone is present in the composition in an amount of 7.5 milligrams or more and wherein said composition ameliorates myopathy, weight loss, or muscle wasting resulting from chronic human immunodeficiency virus type-1 infection.
67. (New) The pharmaceutical composition of claim 66, wherein the oxandrolone is present in the composition in an amount of 7.5 milligrams to 20 milligrams.
68. (New) The pharmaceutical composition of claim 66 wherein the oxandrolone is present in the composition in an amount of 10 milligrams.
69. (New) The pharmaceutical composition of claim 66, wherein the oxandrolone is present in the composition in an amount greater than 20 milligrams.
70. (New) The pharmaceutical composition of claim 66, wherein the composition is in liquid form or solid form.
71. (New) The pharmaceutical composition of claim 66, wherein the oxandrolone is present in the composition in an amount of 20 milligrams.
72. (New) A pharmaceutical composition for ameliorating myopathy, weight loss, or muscle wasting resulting from human immunodeficiency virus type-1 comprising oxandrolone and a pharmaceutically acceptable carrier, wherein the oxandrolone is present in the composition in an amount of 7.5 milligrams or more.
73. (New) The pharmaceutical composition of claim 72, wherein the oxandrolone is present in the composition in an amount of 7.5

Applicant : Joseph R. Berger
Serial No. : 10/052,961
Filed : January 18, 2002
Page 4

milligrams to 20 milligrams.

74. (New) The pharmaceutical composition of claim 72, wherein the oxandrolone is present in the composition in an amount of 10 milligrams.
75. (New) The pharmaceutical composition of claim 72, wherein the oxandrolone is present in the composition in an amount greater than 20 milligrams
76. (New) The pharmaceutical composition of claim 72, wherein the composition is in liquid form or solid form.
77. (New) The pharmaceutical composition of claim 72, wherein the oxandrolone is present in the composition in an amount of 20 milligrams.
78. (New) A pharmaceutical composition comprising oxandrolone and a pharmaceutically acceptable carrier, wherein the oxandrolone is present in the composition in an amount of 7.5 milligrams or more and wherein said composition ameliorates myopathy, weight loss, or muscle wasting resulting from human immunodeficiency virus type-1.
79. (New) The pharmaceutical composition of claim 78, wherein the oxandrolone is present in the composition in an amount of 7.5 milligrams to 20 milligrams.
80. (New) The pharmaceutical composition of claim 78, wherein the oxandrolone is present in the composition in an amount of 10 milligrams.
81. (New) The pharmaceutical composition of claim 78, wherein the oxandrolone is present in the composition in an amount greater than 20 milligrams.

Applicant : Joseph R. Berger
Serial No. : 10/052,961
Filed : January 18, 2002
Page 5

82. (New) The pharmaceutical composition of claim 78, wherein the composition is in liquid form or solid form.
83. (New) The pharmaceutical composition of claim 78, wherein the oxandrolone is present in the composition in an amount of 20 milligrams.
84. (New) The pharmaceutical composition of claim 59, wherein the oxandrolone is administered as an adjunctive therapy.
85. (New) The pharmaceutical composition of claim 66, wherein the oxandrolone is administered as an adjunctive therapy.
86. (New) The pharmaceutical composition of claim 72, wherein the oxandrolone is administered as an adjunctive therapy.
87. (New) The pharmaceutical composition of claim 78, wherein the oxandrolone is administered as an adjunctive therapy.